Bull or Bear, Seeking Alpha is there
Markets change, but our community always has the latest news, in-depth analysis, and powerful stock ratings.

By creating an account using any of the options above, you agree to the Terms of Use & Privacy Policy

Bull or Bear, Seeking Alpha is there
Markets change, but our community always has the latest news, in-depth analysis, and powerful stock ratings.

ABEO Abeona Therapeutics Inc.
Stock Price & Overview

$6.100.31 (+5.35%)4:00 PM 05/16/25

NASDAQ | $USD | Post-Market: $6.06 -0.04 (-0.66%) 7:16 PM

Summary Ratings Financials Earnings Dividends Valuation Growth Profitability Momentum Peers Options Charting

Transcripts & InsightsTranscripts & Insights

SEC FilingsSEC Filings

Press ReleasesPress Releases

Related AnalysisRelated Analysis

Analysis

Ratings:

Select Ratings

Date Range:

Abeona Therapeutics: pz-cel Has Massive Potential For RDEB Patients

Editors' PickAlex PittiMon, Apr. 21115 Comments

Abeona Therapeutics: An Uncertain Pivotal Regulatory Catalyst With Limited Long-Term Upside

Excidium ResearchMon, Apr. 1452 Comments

Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher

IB's ThoughtsSat, Apr. 1210 Comments

Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL

Bhavneesh SharmaThu, May 02, 202411 Comments

Abeona Therapeutics Tanks On CRL From The FDA, But All Hope Is Not Lost

Edward Vranic, CFATue, Apr. 23, 202425 Comments

Abeona: BLA Submission Of EB-101 Gets The Ball Rolling

Terry ChrisomalisWed, Apr. 26, 202322 Comments

Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder Value

Terry ChrisomalisWed, Oct. 19, 202217 Comments

The Right Play On Abeona Therapeutics

Bret JensenWed, Mar. 10, 202118 Comments

Abeona Therapeutics: Undervalued And Nearing An Upswing

Fini BioInvestmentsWed, Mar. 10, 202117 Comments

Abeona: Close To Confirming A Long-Term Bottom

Individual TraderMon, Jan. 18, 20212 Comments

What's Ahead For Abeona Therapeutics

Bret JensenFri, Jan. 03, 20205 Comments

Abeona Therapeutics: Speculative Buy After Financing

Jonathan FaisonTue, Dec. 24, 201921 Comments

Collision With Reality Sends Abeona Stock Spiraling Lower

Mako ResearchWed, Jul. 31, 201943 Comments

Abeona Therapeutics: A True Test Looms As Cash Dwindles

Stephen AyersWed, Jul. 17, 201914 Comments

Abeona Therapeutics: A Potential Leader In Gene Therapy

Pharmyang InvestmentThu, Nov. 01, 201856 Comments

Abeona Therapeutics: The Approval Pathway

Osmium ResearchThu, Aug. 02, 201859 Comments

Abeona Therapeutics: What The Latest Data For ABO-102 Foretells?

BioSci Capital PartnersTue, May 29, 201813 Comments

Your Daily Pharma Scoop: Abeona Presents Strong Data, Glaxo Nucala Treatment Benefit, Rocket Pharma's Gene Therapy Data

Avisol Capital PartnersMon, May 21, 20183 Comments

Your Daily Pharma Scoop: Abeona's ABO-202, Revance Update, Ionis/Biogen's New Collaboration

Avisol Capital PartnersMon, Apr. 23, 20182 Comments

Your Daily Pharma Scoop: Abeona Update, Alexion Data, Solid Biosciences Setback

Avisol Capital PartnersFri, Mar. 16, 20183 Comments

Abeona Therapeutics: Data Update - Part 2

Jonathan FaisonMon, Feb. 12, 201845 Comments

Your Daily Pharma Scoop: Abeona Surges, Gilead Results, Biogen Setback

Avisol Capital PartnersThu, Feb. 08, 20187 Comments

This ROTY Contender Just Released Promising Data

Jonathan FaisonThu, Feb. 08, 201842 Comments

Your Daily Pharma Scoop: Abeona's EB-101 Granted RMAT Designation, Teva To Raise Debt, Pfizer Reports Results

Avisol Capital PartnersWed, Jan. 31, 2018

Abeona Therapeutics: Continued Upside In 2018

Jonathan FaisonFri, Jan. 26, 201824 Comments

Abeona Therapeutics: The Upcoming Neurocognitive Catalyst

Biotech ResearchTue, Jan. 16, 201845 Comments

2018 Could Be Another Solid Year For Abeona Therapeutics

Avisol Capital PartnersTue, Jan. 16, 2018

Relieving Suffering From Genetic Disease - Abeona Therapeutics

Editors' PickScientist of FortuneWed, Dec. 06, 201725 Comments

Abeona Therapeutics: Transitioning To Late-Stage Studies

Jonathan FaisonSun, Aug. 27, 201731 Comments

Abeona Therapeutics - String Of Pearls Strategy With Numerous Catalysts And A Lot Of Upside

World's GreatestTue, Aug. 22, 2017282 Comments

Abeona: Preparing For Liftoff - The Next AveXis?

Editors' PickWorld's GreatestTue, Feb. 14, 2017409 Comments

Abeona Director Implicated In 'Pump And Dump' Lawsuit With SEC Investigation, Price Target Of Zero

Mako ResearchMon, Jan. 09, 201795 Comments

Abeona - Considerable Upside Potential With Near Term Catalysts

World's GreatestThu, Dec. 22, 201650 Comments

Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside

Editors' PickMako ResearchMon, Dec. 12, 201685 Comments

Abeona Therapeutics: A Promising Gene Therapy Story

Jonathan FaisonMon, Oct. 10, 201614 Comments

Abeona Therapeutics Stock Is On A Tear; COO, Jeff Davis, Tells Investors Why Gene Therapy Is Here To Stay

Investor InitiativesWed, Sep. 21, 20163 Comments

Investing Groups

Portfolios

Find & Compare

Subscriptions

ABEO Abeona Therapeutics Inc.
Stock Price & Overview

Analysis

People Also Follow

Similar to ABEO

ETFs Holding ABEO

ABEO Abeona Therapeutics Inc.Stock Price & Overview

Analysis

People Also Follow

Similar to ABEO

ETFs Holding ABEO

ABEO Abeona Therapeutics Inc.
Stock Price & Overview